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Methods: We used stable isotope labeling kinetics (SILK-ApoE and SILK-Ab) to measure the effect
of bexarotene on the turnover rate of apoE and Ab peptides and stable isotope spike absolute quan-
titation (SISAQ) to quantitate their concentrations in the cerebrospinal fluid (CSF). Normal subjects
were treated for 3 days with bexarotene (n5 3 women, 3men, average 32 years old) or placebo (n5 6
women, average 30.2 years old) before administration of C13-leucine and collection of plasma and
CSF over the next 48 hours. Bexarotene concentrations in plasma and CSF were also measured.
Results: Oral administration of bexarotene resulted in plasma levels of 1 to 2 mM; however, only low
nM levels were found in CSF. Bexarotene increased CSF apoE by 25% but had no effect on meta-
bolism of Ab peptides.
Discussion: Bexarotene has poor CNS penetration in normal human subjects. Drug treatment re-
sulted in a modest increase in CSF apoE levels. The absence of an effect on Ab metabolism is likely
reflective of the low CNS levels of bexarotene achieved. This study documents the utility of SILK-
ApoE technology in measuring apoE kinetics in humans.
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Alzheimer’s disease (AD) typically occurs late in life [1]
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commons.org/licenses/by-nc-nd/4.0/).(Ab) from the brain [2,3]. Elevated levels of soluble forms of
Ab peptides are associated with the perturbation of synaptic
function and neural network activity leading to the cognitive
deficits observed in the disease [4].
The most important genetic risk factor for sporadic AD
is allelic variation in the Apolipoprotein E (APOE) gene,
and possession of an APOE ε4 allele dramatically increases
disease risk [5]. ApoE plays critical roles in the clearance
and deposition of Ab peptides [6]. ApoE scaffolds the for-
mation of high-density lipoprotein (HDL) particles that
traffic cholesterol and phospholipids throughout the brain.
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tellano et al. [7] reported that the apoE4 isoform slows Ab
clearance from brain interstitial fluid significantly more
than the apoE2 and apoE3 isoforms in animals. Targeting
Ab clearance pathways have emerged as a promising ther-
apeutic target.
We have demonstrated that apoE-containing HDL parti-
cles act to promote the proteolytic clearance of Ab peptides
from the brain of mouse models of AD. Significantly, the
APOE ε4 gene product is impaired in this function [8]. In an-
imal models, chronic induction of apoE and/or HDL expres-
sion in the brain is associated with reduced Ab levels and
improved cognitive function [8–12]. ApoE and its lipid
transporters ABCA1 and ABCG1 are transcriptionally
regulated by ligand-activated, type II nuclear receptors,
most prominently liver X receptors (LXR) and peroxisome
proliferator-activated receptor gamma (PPARg), which
form functional dimeric transcription factors through their
interactions with retinoid X receptors (RXR) [13,14].
Importantly, oral administration of agonists of PPARg and
LXRs to animal models of AD results in the proteolytic
degradation of soluble Ab peptides in the interstitial fluid
and by microglia [8,15,16].
Cramer et al. [17], and others [18,19], have reported that
administration of the RXR agonist bexarotene increased
brain apoE expression, elevated HDL levels, and enhanced
normal Ab clearance mechanisms. Bexarotene
simultaneously activated the PPARs and LXRs in the brain
[20,21] and reduced soluble Ab levels in the brain and
interstitial fluid [17–19,22]. The reduction in soluble Ab
peptide levels was associated with improved neural
network activity and improved memory and cognition
[17,18,23,24].
Bexarotene is a highly specific, Food and Drug Adminis-
tration (FDA)–approved RXR agonist [25] with a favorable
safety profile [26]. Bexarotene has been used clinically for
the treatment of cutaneous T-cell lymphoma with chronic
daily oral administration of the drug at doses of 300 mg/
m2/d [27].
The objective of this proof of mechanism clinical trial
was to determine whether the RXR agonist bexarotene acts
in normal human subjects to increase the cerebrospinal fluid
(CSF) levels of apoE and alter the clearance of Ab. This
study used stable isotope labeling kinetics (SILK) to eval-
uate the synthesis and clearance rate of apoE [28] and Ab
[2,7,29] in the CSF.Table 1
Subjects: The average age, weight, sex, and APOE genotype of the subjects
enrolled in the study
Placebo Bexarotene
Age (y) 30.2 6 6.6 32 6 9.6
Weight (kg) 66.9 6 7.1 84.6 6 23.2
Female sex (%) 6 (100) 3 (50)
APOE genotype 3/3 3/32. Methods
2.1. Study design
The trial was conducted as a double-blinded study, to
measure the effect of bexarotene on the synthesis and clear-
ance of Ab peptides and production of apoE in the human
brain. Compass Research, Tampa, Florida, enrolled the sub-
jects and conducted the trial. The protocol was approved bySchulman Associates Institutional Review Board, Inc. All
subjects signed informed consent forms before enrollment
in the study. This study was conducted under Investigational
New Drug Application 121548.
This study used SILK to measure production and clear-
ance of Ab peptides [29] and apoE [28,30] in the CSF of
healthy volunteers. Subjects were administered 13C6-
labeled leucine over 9 hours, and CSF samples were
collected over the subsequent 48 hours. The incorporation
of 13C6-labeled leucine into Ab and apoE isolated from
CSF was measured by mass spectrometry (MS), allowing
determination of the biosynthesis and clearance of these
biomolecules. Quantitation of the absolute levels of Ab
and apoE was achieved by adding Ab and apoE internal
standards to the CSF samples.2.2. Subjects
The study population consisted of three men and nine
women, aged 21 to 49 years all carrying the APOE ε3/ε3 ge-
notype. The treatment, and average gender, age, weight, and
body mass index of the subjects are detailed in Table 1. A
sample size of six subjects per group allowed an 80% chance
of observing a 47% change in Ab AUC1-12 hours. There was a
balanced randomization process in which subjects were ran-
domized in a 1:1 ratio to either drug or placebo. Subjects
were randomized into one of two groups based on an atmo-
spheric (atmospheric noise) method for randomization. One
group was assigned the active product, and the other group
was assigned an identical placebo based on first subject
received, first randomization assignment. Study subjects
and researchers were blinded as to which product contained
the active product or placebo.2.3. Procedures
The subjects received either placebo or 225 mg of bex-
arotene (Targretin; Valeant Pharmaceuticals, Laval,
Quebec) at 9 AM and 7 PM for 5 days (450 mg/d;
300 mg/m2/d). On the morning of the fourth day of dosing,
subjects were admitted to the clinical research unit and
administered 13C6 leucine through an intravenous catheter
as an initial bolus of 3 mg/kg (10 minutes), followed by
9 hours of continuous intravenous infusion at a rate of
2 mg/kg/h. A second intravenous catheter was placed in
the contralateral antecubital vein to obtain blood samples.
A lumbar catheter was inserted in the L3 to L4 interspace
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through hour 15 of the study and then every other hour
up to 48 hours. CSF samples were taken hourly until
hour 36 and then every other hour until hour 48. No serious
adverse events were reported during the study period.
Three subjects had increased triglyceride levels greater
than 200 mg/dL. One subject had increased cholesterol
levels greater than 200 mg/dL. Two subjects had abnormal
thyroid levels. Two subjects had abnormal aspartate amino-
transferase/alanine aminotransferase levels. All abnormal-
ities were resolved by the end of the study without
treatment. Other AEs included head ache (nine subjects),
burping (one subject), rashes (one subject), nausea (one
subject), and bloating (one subject).2.4. Statistical analysis
Statistical analysis was performed using R (version
3.1.2). Weighted area under the curve (AUC) was calculated
using trapezoidal AUC function and dividing by the delta ab-
scissa. Comparisons between drug and placebo groups were
made using the Student’s t-test. Graphs show average695%
confidence intervals (CIs), unless otherwise indicated.2.5. Analytical procedures2.5.1. Bexarotene pharmacokinetics
Bexarotene concentration was measured in plasma and
CSF samples using gas chromatography and/orMS. Briefly,
a known amount of internal standard (13C4-labeled bexaro-
tene) was added to each plasma and CSF sample. Bexaro-
tene (and 13C4-labeled bexarotene) was extracted from
the sample via liquid–liquid extraction [31]. Bexarotene
and 13C4-labeled bexarotene were quantitated using
selected-reaction monitoringMS. A standard curve consist-
ing of samples containing 13C4-labeled bexarotene at a con-
stant concentration and bexarotene at varying
concentrations that covered the expected concentration
range of the drug in the patient samples was constructed.
The amount of endogenous bexarotene was quantified
through integration of the product ion peaks and taking
the ratio of the unlabeled and/or labeled bexarotene. Sam-
ples in which the amount of bexarotene measured in CSF
was below the limit of quantitation (LOQ) were recorded
as ,0.021 mM.
2.5.2. Measurement of free plasma leucine levels
Plasma leucine concentrations were quantitated using
Agilent 6890 gas chromatography-mass spectrometry (GC-
MS) [32]. Selected ion monitoring was used to detect
13C6-labeled (m/z 349) and unlabeled (m/z 355) leucine.
The molar enrichment of 13C6-labeled leucine was deter-
mined using calibration curves prepared with isotopic stan-
dards (Cambridge Isotope Laboratories, Andover, MA,
USA).2.5.3. Quantitation and metabolism of Ab40 and total Ab in
human CSF samples
CSF samples were combined with an internal standard
and incubated with anti-Ab (central domain) antibody-
bound Sepharose beads [29]. After washing, the captured
proteins were eluted from the antibody beads and digested
with Lys-N. The resultant peptides were dried and re-
solubilized for MS and injected onto a nanoflow liquid chro-
matography (LC) reverse phase column coupled directly
online with a triple quadrupole mass spectrometer (TSQ
Vantage; Thermo Scientific, San Jose, CA, USA). Ab40
[28–40] and total Ab [16–27] peptides were monitored at
3 m/z ratios, corresponding to the unlabeled, the 13C6-
leucine labeled, and the internal standard–labeled peptides.
Each parent peptide was subjected to collision-induced
dissociation (CID) and its product ions measured and their
peak areas integrated.
Two standard curves and two sets of three quality control
(QC) samples were analyzed concurrently with patient sam-
ples. One standard curve (SISAQ) consists of known concen-
trations of 13C6-leucine– and
12C6-leucine–labeled Ab and is
used for calculating the concentration of metabolically
labeled and unlabeled Ab in the sample. The other standard
curve (SILK) contains Ab that has been metabolically
labeled with 13C6-leucine at various ratios and serves as a
way to standardize the relative labeling data.
2.5.4. Quantitation and metabolism of apolipoprotein E in
cerebrospinal fluid samples
A known amount of internal standard was added to each
CSF sample. These samples, along with two standard curves
and QC samples, were incubated with anti-apoE antibody–
bound beads, washed, then eluted and digested with trypsin
[29]. The resultant peptides were dried and injected using
nanoflow LC onto a reverse phase column and separated
and eluted into the mass spectrometer using a gradient of
increasing organic mobile phase. ApoE (177-185) was
monitored at 3 m/z ratios, corresponding to the unlabeled,
the 13C6-leucine labeled, and the internal standard–labeled
peptide. Each parent peptide was subjected to CID and its
product ions measured and integrated. Quantitation was con-
ducted by integrating the product ion peaks and taking the
ratio of the endogenous apoE/internal standard apoE. The ra-
tio of labeled to unlabeled apoE was plotted over 48 hr.3. Results
3.1. Bexarotene plasma and CSF pharmacokinetics
The concentration of bexarotene was measured in the
plasma and CSF of all subjects beginning on the fourth
day of drug treatment over a period of 48 hours. Bexarotene
was only detected in the plasma of subjects who were dosed
with the drug, and all treated subjects showed similar phar-
macokinetic profiles (Fig. 1). Average peak plasma concen-
trations were 1.46 6 0.62 mM (average of four dosings per
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dose) 5 7.58 6 3.80 mM. These data demonstrate plasma
pharmacokinetics similar to that previously reported [31].
The CSF bexarotene levels were below the LOQs of the
assay (0.021 mM) for .95% samples, regardless of subject
treatment. In 5 of 6 bexarotene-treated subjects, at least
one CSF sample with bexarotene levels higher than the
LOQ was measured (Fig. 1). We estimated the plasma-to-
CSF ratio of bexarotene concentration in this subset of sam-
ples by dividing the concentration of bexarotene in plasma
by corresponding peak of bexarotene detected in the CSF
(or LOQ). In samples in which bexarotene concentration
was accurately measured, we estimated that the plasma-to-
CSF ratio was approximately 85:1 (Fig. 1).3.2. Effect of bexarotene on Apolipoprotein E3.2.1. Stable isotope labeling kinetics
SILK was used to measure the fractional synthesis and
clearance rates (FSR and FCR) of apoE in each subject by
quantitating the amount of 13C6-leucine–labeled and unla-
beled apoE in CSF at each of the time points CSF was ac-
quired. The SILK data are plotted as the normalized
tracer-to-tracee ratio (TTR), which is the ratio of the amount
of 13C6-leucine–labeled apoE divided by the amount of un-
labeled apoE in CSF. The mean normalized SILK-ApoE
curves showed maximum stable isotope labeling of apoEFig. 1. Pharmacokinetics of bexarotene. The concentration of bexarotene in plasm
receiving drug. The average maximal concentration of drug in plasma was 1.466 1
in CSF was below the level of detection (0.021 mM) in.95% of samples. In sample
were approximately 20 nM.occur at approximately 24 to 25 hours after initiation of
13C6-leucine infusion (Fig. 2A). The mean FSR of apoE
was measured between 6 and 17 hours (Fig. 2B) and the frac-
tional clearance rate (FCR), determined over the period of 23
to 48 hours (Fig. 2C). There was no significant difference in
the fractional synthesis (P5 .8578) or clearance (P5 .4646)
of apoE in the CSF of subjects treated with bexarotene or
placebo when measured after 3 days of drug treatment.
3.2.2. Stable isotope spike absolute quantitation
The absolute concentration of apoE in the CSF was calcu-
lated by adding the concentration values for the unlabeled
and 13C6-leucine–labeled apoE. The apoE concentrations
of the individual subjects (Fig. 2D), and their average values
(695% CIs; Fig. 2E) were quantitated. There was a signifi-
cant 25% increase (P 5 .0367, Glass’s delta effect size of
2.55) in the mean weighted area under the full concentration
curves of apoE in the CSF of the bexarotene-treated subjects
(Fig. 2F) compared with those treated with placebo.
This result suggests that bexarotene significantly increased
total apoE concentration in the central nervous system (CNS)
of normal healthy individuals with APOE ε3/ε3 genotype.
Using the concentration of labeled apoE and the average
leucine TTR observed in each subject, the amount of newly
generated apoE was calculated. The increase in newly gener-
ated CSF apoE approached but did not reach statistical signif-
icance between the two treatment groups (P5 .0538; Fig. 2I)
as indicated by the mean area under the concentration curvea and cerebrospinal fluid (CSF) samples was measured hourly in subjects
mM, and the Tmax was 3.456 11.41 h after dosing. The levels of bexarotene
s in which bexarotene could reliably be quantified, peak CSF concentrations
Fig. 2. Stable isotope labeling kinetics (SILK) and stable isotope spike absolute quantitation of ApoE in cerebrospinal fluid (CSF). The SILK data are plotted as
the normalized tracer-to-tracee ratio (TTR), which is the amount of 13C6-Leu labeled apoE divided by the amount of unlabeled apoE. (A) The mean values are
plotted6 95% confidence intervals (CIs) of placebo- (blue) and bexarotene- (red) treated subjects. (B) The fractional synthesis rates (FSRs), measured from 6 to
17 hours or (C) fractional clearance rates (FCRs) determined from 23 to 48 hours were not significantly different between placebo- and drug-treated subjects.
The absolute concentration of apoE in the CSF was calculated by adding the concentration values for the unlabeled and 13C6-labeled apoE. (D) ApoE concen-
trations of the individual subjects treated with placebo (blue) or bexarotene (red) and (E) their average values (695% CIs). (F) There was a significant 25%
increase (P 5 .0367) in the mean weighted area under the full concentration curves of apoE in the CSF of the bexarotene-treated subjects. Quantitation of
the amount of newly synthesized apoE in (G) individual subject and (H) their average values (695%CIs) revealed (I) a nonsignificant change between placebo-
and bexarotene-treated subjects.
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dividual subjects (Fig. 2G) or group averaged values (Fig. 2H;
695%CIs). These data suggest that therewas no difference in
the rates of apoE synthesis in the brain whenmeasured 3 days
after initiation of bexarotene treatment. The analysis of the
lipidation status of apoE did not yield meaningful results
owing to poor resolution of the analytic techniques.3.3. CSFAb3.3.1. Stable isotope labeling kinetics
The mean normalized SILK-Ab total between placebo-
and drug-treated subjects was compared and shown in
Fig. 3A and Fig. 3B. The FSR (Fig. 3C) and FCR
Fig. 3. Stable isotope labeling kinetics (SILK) of total Ab and of Ab40 in cerebrospinal fluid (CSF). The synthesis and clearance rates of total Ab were
measured in CSF using an Ab1-x capture antibody. The SILK data are plotted as the normalized tracer-to-tracee ratio (TTR), which is the amount of 13C6-
Leu labeled Ab divided by the amount of total unlabeled Ab. (A) The values for the individual subject treated with placebo (blue) or bexarotene (red), and
(B) the mean values are plotted6 95% confidence intervals (CIs). (C) The fractional synthesis rates (FSRs), measured from 6 to 17 hours. (D) Fractional clear-
ance rates (FCRs) determined from 23 to 48 hours were not significantly different between placebo- and drug-treated subjects. The SILK data are plotted as the
normalized TTR, which is the amount of 13C6-Leu labeled Ab40 divided by the amount of unlabeled Ab40. (E) The values for the individual subject and (F) the
mean values are plotted6 95% CIs. (G) The FSRs, measured from 6 to 17 hours or (H) FCRs determined from 23 to 48 hours were not significantly different
between placebo- and drug-treated subjects.
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tween the placebo- and drug-treated groups. These results
demonstrate that the fractional synthesis or clearance of
Ab total in CSF of normal healthy individuals treated with
placebo was comparable to that of individuals treated for
3 days with bexarotene. Similarly, there was no difference
observed in the turnover of Ab40 between the bexarotene-
and placebo-treated subjects at this time (Fig. 3E–3H).
3.3.2. Stable isotope spike absolute quantitation
Quantitation of the amount of Ab total (Fig. 4A) and
Ab40 (Fig. 4D) in the CSF in the individual subjects or the
mean values of Ab total (Fig. 4B) or Ab40 (Fig. 4E) demon-
strated that there was no significant difference in the absolute
levels of Ab total (Fig. 4C) or Ab40 (Fig. 4F) peptides be-
tween treatment groups.
Evaluation of the concentration of newly generated (i.e.,
13C6-leucine labeled) Ab total (Fig. 4G) and Ab40 (Fig. 4I)
was measured. However, there was no difference in the
amount of Ab peptides synthesized (Fig. 4H and 4K) or
cleared (Fig. 4I and 4L) between bexarotene- and placebo-
treated subjects.
In summary, bexarotene treatment had no effect on the
metabolism of Ab peptides in normal human subjects with
the current treatment regimen.4. Discussion
Nuclear receptors are ligand-activated transcription fac-
tors that act broadly to regulate cellular metabolism [14].
In the brain, the principal type II nuclear receptors include
the PPARs and LXRs, which form obligate heterodimers
with RXRs to form a functional transcription factor
[15,33]. The dimeric receptor binds to sequence-specific
motifs in the promoter and enhancers of their target genes
and on ligand binding induces gene expression [34]. These
nuclear receptors are termed “permissive” as ligation of
either member of the dimeric receptor is sufficient to stimu-
late gene expression. In the brain, the expression of the
APOE gene is directly regulated by LXR:RXR, as are the
lipid transporters ABCA1 and ABCG1, which act to transfer
phospholipids and cholesterol to apoE. ApoE serves as a
scaffold for the formation of HDL particles. PPARg:RXR
can act indirectly on the enhancers of these genes and
through other mechanisms to promote apoE expression
and elevate brain HDL levels [20]. The stimulation of brain
HDL concentration results in the enhanced proteolytic
degradation of soluble Ab peptides and their clearance
from the brain [8,17]. We reasoned that provision of an
RXR agonist would provide an efficient means to drive
apoE expression in the brain. Indeed, bexarotene treatment
resulted in the rapid increase in apoE-based HDLs in the
interstitial fluid of animal models, coincident with a decrease
in soluble Ab levels [17,18,22]. The reduction in brain
soluble Ab levels was associated with enhanced neural
network activity and improved memory and cognition inmurine models of AD [17,18,23,24]. The present study
was a proof of mechanism trial to ascertain if bexarotene
acts similarly in the normal human brain.
We report that bexarotene was poorly CNS penetrant in
normal subjects, reflected by the low levels of drug found
in the CSF. The bexarotene levels in CSF were below the
LOQ of the assay in .95% of samples. However, five of
the six subjects treated with the drug had levels of bexaro-
tene above the LOQ in a small subset of samples. The ratio
of peak plasma to CSF drug levels was approximately 85:1
with maximal bexarotene levels in the low nM range. The
poor CNS exposure to bexarotene observed here was similar
to that reported by Rotstein et al. [35] in the baboon where
18F-labeled bexarotene was found to rapidly enter the brain
and distribute uniformly. However, the brain:tissue levels
were on the order of 50:1. The detection of only low concen-
trations of bexarotene in the CSF was unexpected because in
mice, bexarotene is freely CNS permeable [19,36,37]. The
low CSF levels in humans may arise from its poor blood
brain barrier and/or blood to CSF barrier permeability.
Alternatively, bexarotene may be efficiently effluxed from
the brain by p-glycoprotein or related transporters.
We observed that bexarotene-treated subjects had higher
concentration of total apoE in CSF. The modest, but signif-
icant (P 5 .0367), 25% increase in apoE concentration in
CSF reflected the weighted area under the full concentration
curve over the interval from 72 to 120 hours. The elevated
apoE concentration likely arises from a drug-induced in-
crease in steady state mRNA levels achieved during the first
3 days of drug treatment. A similar effect was observedwhen
the amount of newly synthesized apoE was quantitated;
however, it approached, but did not reach, significance
(P 5 .0538). There was no difference between treatment
groups in the kinetics of apoE synthesis or clearance in
CSF. The drug-induced change in steady state metabolism
over several days of treatment measured by SILK is analo-
gous to that previously reported by Sheline et al. [38] for Ab.
The net increase in CSF apoE levels was achieved with
levels of bexarotene estimated to be in the low nM range.
The Kd of bexarotene for RXRs is approximately 20 nM;
thus, we observed target engagement at modest levels of re-
ceptor occupancy. The magnitude of the increase in humans
(25%) is significantly less than that elicited in the brain
(.200%) [17], or interstitial fluid (250%) [22] of
bexarotene-treated mice. In rats, LXR agonist treatment re-
sulted in an approximate 200% increase in CSF apoE levels
[12].
Metabolic curves for the synthesis and clearance of total
Ab and Ab40 from the drug and placebo-treated subjects
showed that bexarotene had no effect on the synthesis or
clearance of Ab in CSF, nor was there a difference in the to-
tal amount of the peptides in the CSF. The absence of any
alteration of Ab metabolism is likely reflective of the small
changes in apoE levels we observed.
These data clearly demonstrate that bexarotene is poorly
CNS penetrant in the normal human brain. However, it is
Fig. 4. Stable isotope spike absolute quantitation of total Ab and Ab40 and newly synthesized total Ab and Ab40 in cerebrospinal fluid (CSF). The absolute
concentration of total Ab and Ab40 peptides in the CSF was calculated by adding the concentration values for the unlabeled and 13C6-labeled peptides using
antibodies directed at Ab1-x or at the C-terminal Ab40 epitope. (A) Total Ab or (D) Ab40 concentrations of the individual subjects treated with placebo
(blue) or bexarotene (red) and (B, E) their average values (695%confidence intervals [CIs]). Therewas no significant difference in themeanweighted area under
the full concentration curves of (C) total Ab or (F) Ab40 in the CSF of the bexarotene-treated subjects. The absolute concentration of newly synthesized total Ab
andAb40 peptides in theCSFwas calculated by adding the concentrationvalues for the unlabeled and 13C6-labeledAb peptides at each time point.Quantitation of
themean amount of newly synthesized (G) total Ab and (J) Ab40 (695%CIs) in placebo- and bexarotene-treated subjects revealed no difference in the amount of
Ab peptides (H, K) synthesized or (I, L) cleared in the placebo-treated compared with bexarotene-treated subjects. Abbreviation: AUC, area under the curve.
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tagne et al. [39] have recently reported that the blood–brain
barrier in the hippocampus was compromised in individuals
with mild cognitive impairment. Thus, therapeutically rele-
vant levels of the drug might be achieved in individuals even
at the earliest stages of AD. Cummings and coworkers per-
formed a randomized, placebo-controlled phase II trial of
bexarotene in 20 mild-to-moderate AD patients. They re-
ported that 30 days of bexarotene treatment (using a 30%
lower dose) resulted in a statistically significant reduction
in brain amyloid burden with a parallel increase in plasma
Ab42 in individuals with an APOE ε3 genotype, whereas
those possessing an APOE ε4 allele exhibited no change
[40]. The basis for the differential effects associated with
the two APOE isoforms is unknown. It should be noted
that the present study enrolled only APOE ε3 carriers a study
design that was adopted due to theoretical concerns that the
APOE ε4 genotype may represent a toxic gain of function,
and induction of elevated APOE ε4 expression might have
negative side effects. However, the work by Cummings
et al. [40], and other clinical trials have provided no evidence
for any negative CNS-based effects. Consistent with the
findings of Cummings et al., Pierrot et al. [41] recently re-
ported a case study demonstrating that 6 months of bexaro-
tene treatment in an individual with mild AD resulted in
improved cognition. Lerner et al. [42] reported that treat-
ment of schizophrenic patients with bexarotene resulted in
significant symptomatic improvement, arguing for biologi-
cally relevant levels of drug in the brain of these patients.
Thus, it is possible that bexarotene’s poor CNS penetrance
may not be a barrier to its therapeutic use in AD. The utility
of nuclear receptor agonists in the prevention or treatment of
AD is supported by the recent report by Heneka et al. [43]
who found that chronic administration of pioglitazone, an
agonist of PPARg:RXR, reduced the risk of dementia by
47% in a large population of elderly diabetics.
It is noteworthy that McFarland et al. [44] reported dra-
matic effects of bexarotene in a rodent model of Parkinson’s
disease at bexarotene doses that were the equivalent of 1% of
the FDA-approved dosage used in this study. The salutary ef-
fects of the drugwere attributed to its activation of the nuclear
receptor Nurr1 (NR4A2). This study argued that bexarotene
exhibited neuroprotective and behavioral effects through
Nurr1 target genes, including CREB and BDNF. This obser-
vation is consistent with recent work that has shown that liga-
tion of PPARa:RXR induces BDNF expression and improved
memory in a mouse model of AD [45]. Moreover, bexarotene
has been reported to have direct effects on neurons in mouse
models of AD [46] and aging [47] increasing expression of
synaptic proteins and preservation of dendrites [48]. Simi-
larly, in anmouse amyotrophic lateral sclerosis model, bexar-
otene treatment reduced neuronal death and increased
survival [49].
The present study argues that treatment of individuals
with an intact BBB are unlikely to benefit from bexarotene
administration. However, it remains a formal possibility itmay act through non-apoE–dependent mechanisms at low
drug concentrations. The report by Cummings et al. [40] in-
dicates that bexarotene has salutary effects in mild-to-
moderate AD patients.
Indeed, this study provides a clear rationale for a larger
phase II/III trial over longer periods to test its efficacy on
memory and cognition.
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1. Systematic review: The authors searched PubMed
for studies investigating retinoid X receptors
(RXR) agonists in Alzheimer’s disease (AD). There
are two reports of its use in AD patients, which are
cited.
2. Interpretation: We report that the RXR agonist bexar-
otene is poorly central nervous system (CNS) pene-
trant in normal humans after oral administration.
However, bexarotene treatment modestly elevates
CSF apoE levels but is without effect on b amyloid
homeostasis.
3. Future directions: Bexarotene has recently been re-
ported to have effects in AD patients suggesting
that further study of this drug is necessary. However,
given the poor CNS exposure in normal individuals,
these data suggest that bexarotene may not be of util-
ity in prevention of AD.
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